Intraperitoneal recombinant human endostatin combined with chemotherapy for refractory malignant ascites due to gastrointestinal cancer: A pilot study

Hepato-Gastroenterology

Volumn 60, Issue 122, 2013, Pages 118-123

  Xue, Sheng Liu ^a   Deng, Xia ^a   Liu, Yang ^a   Su, Hua Fang ^a   Hu, MeiLong ^a   Xie, Cong Ying ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Combined therapy; Gastrointestinal cancer; Intraperitoneal chemotherapy; Recombinant human endostatin; Refractory malignant ascites

Indexed keywords

CISPLATIN; DEXAMETHASONE; FLUOROURACIL; RECOMBINANT ENDOSTATIN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; HUMAN; MALIGNANT ASCITES; MULTIPLE CYCLE TREATMENT; PILOT STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; TACHYCARDIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASCITES; ENDOSTATINS; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; INJECTIONS, INTRAPERITONEAL; MALE; MIDDLE AGED; PILOT PROJECTS; QUALITY OF LIFE; RECOMBINANT PROTEINS;

EID: 84877707644     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge12497     Document Type: Article

References (30)

1. Ayantunde AA, Parsons SL: Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol 2007; 18:945-949. (Pubitemid 47054094)
2. Becker G, Galandi D, Blum HE: Malignant ascites: systematic review and guideline for treatment. Eur J Cancer 2006; 42:589-597. (Pubitemid 43343680)
3. Rosenberg SM: Palliation of malignant ascites. Gastroenterol Clin North Am 2006; 35:189-199.
4. Zang RY, Zhang ZY, Li ZT, et al.: Impact of secondary cytoreductive surgery on survival of patients with advanced epithelial ovarian cancer. Eur J Surg Oncol 2000; 26:798-804.
5. Kobold S, Hegewisch-Becker S, Oechsle K, et al.: Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites? Oncologist 2009; 14:1242-1251.
6. Garrison RN, Galloway RH, Heuser LS: Mechanisms of malignant ascites production. J Surg Res 1987; 42:126-132. (Pubitemid 17024827)
7. Ammouri L, Prommer EE: Palliative treatment of malignant ascites: profile of catumaxomab. Biologics 2010; 4:103-110.
8. Hamilton CA, Maxwell GL, Chernofsky MR, et al.: Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecol Oncol 2008; 111:530-532.
9. Numnum TM, Rocconi RP, Whitworth J, et al.: The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol Oncol 2006; 102:425-428. (Pubitemid 44353660)
10. Pichelmayer O, Gruenberger B, Zielinski C, et al.: Bevacizumab is active in malignant effusion. Ann Oncol 2006; 17:1853.
11. Parsons SL, Watson SA, Steele RJ: Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites. Eur J Surg Oncol 1997; 23:526-531. (Pubitemid 28059777)
12. Beattie GJ, Smyth JF: Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites. Clin Cancer Res 1998; 4:1899-1902. (Pubitemid 28369173)
13. Ling Y, Yang Y, Lu N, et al.: Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun 2007; 361:79-84. (Pubitemid 47102270)
14. Lu N, Ling Y, Gao Y, et al.: Endostar suppresses invasion through downregulating the expression of matrix metalloproteinase-2/9 in MDA-MB-435 human breast cancer cells. Exp Biol Med 2008; 233:1013-1020.
15. Wei HM, Qin SK, Yin XJ, et al.: Therapeutic features of endostar, a modified endostatin, on ascites tumor in mice. Nan Fang Yi Ke Da Xue Xue Bao 2010; 30:1509-1513. (In Chinese with English abstract).
16. Smith EM, Jayson GC: The current and future management of malignant ascites. Chin Oncol R Coil Radiol 2003; 15:59-72. (Pubitemid 36348121)
17. Barni S, Cabiddu M, Ghilardi M, et al.: A novel perspective for an orphan problem: old and new drugs for the medical management of malignant ascites. Crit Rev Oncol Hematol 2011; 79:144-153.
18. Li XQ, Shang BY, Wang DC, et al.: Endostar, a modified recombinant human endostatin, exhibits synergistic effects with dexamethasone on angiogenesis and hepatoma growth. Cancer Lett 2011; 301:212-220.
19. Arafa HM, Abdel-Hamid MA, El-Khouly AA, et al.: Enhancement by dexamethasone of the therapeutic benefits of cisplatin via regulation of tumor angiogenesis and cell cycle kinetics in a murine tumor paradigm. Toxicology 2006; 222:103-113.
20. Egberts JH, Schniewind B, Pätzold M, et al.: Dexamethasone reduces tumor recurrence and metastasis after pancreatic tumor resection in SCID mice. Cancer Biol Ther 2008; 7:1044-1050.
21. Luo JC, Shin VY, Liu ES, et al.: Dexamethasone delays ulcer healing by inhibition of angiogenesis in rat stomachs. Eur J Pharmacol 2004; 485:275-281. (Pubitemid 38134425)
22. Heiss MM, Murawa P, Koralewski P, et al.: The tri-functional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int J Cancer 2010; 127:2209-2221.
23. Yonemori K, Okusaka T, Ueno H, et al.: FP therapy for controlling malignant ascites in advanced pancreatic cancer patients. Hepato-gastroenterol 2007; 54:2383-2386.
24. Imamoto H, Oba K, Sakamoto J, et al.: Assessing clinical benefit response in the treatment of gastric malignant ascites with non-measurable lesions: a multicenter phase II trial of paclitaxel for malignant ascites secondary to advanced/recurrent gastric cancer. Gastric Cancer 2011; 14:81-90.
25. Oriuchi N, Nakahima T, Mochiki E, et al.: A new, accurate and conventional five-point method for quantitative evaluation of ascites using plain computed tomography in cancer patients. Jpn J din Oncot 2005; 35:386-390.
26. Kitayama J, Ishigami H, Kaisaki S, et al.: Weekly intravenous and intraperitoneal paclitaxel combined with S-1 for malignant ascites due to advanced gastric cancer. Oncology 2010; 78:40-46.
27. Easson AM, Bezjak A, Ross S, et al.: The ability of existing questionnaires to measure symptom change after paracentesis for symptomatic ascites. Ann Surg Oncol 2007; 14:2348-2357. (Pubitemid 47174909)
28. Sebastian M: Review of catumaxomab in the treatment of malignant ascites. Cancer Manag Res 2010; 2:283-286.
29. Colombo N, Mangili G, Mammoliti S, et al.: A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites. Gynecol Oncol 2012; 125:42-47.
30. Nicoletto MO, Dalia Palma M, Donach ME, et al.: Positive experience of intraperitoneal chemotherapy followed by intravenous chemotherapy in heavily pretreated patients with suboptimal residual ovarian cancer and primary peritoneal cancer. Tumori 2010; 96:918-925.